Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
For best results when printing this announcement, please click on link below: bioAffinity Technologies to Present New Perspectives on CyPath® Lung’s Use for Cancer Risk Assessment at CHEST 2026 Chief Medical Officer Gordon Downie, MD, to host CHEST 2026 Learning Theater on clinical use of CyPath® Lung Presentation to a
The company says its investigational sputum test can detect multiple lung inflammation protein biomarkers tied to asthma and COPD drug targets.
bioAffinity Technologies will present new research data at CHEST 2026 on investigational sputum-based tests for asthma and COPD inflammation. Study findings indicate the approach can detect multiple inflammation-related biomarkers, aiming to profile patients for precision monitoring over time. Work uses the company’s f